Sensiotec Unveils Version 2.0 Of Virtual Medical Assistant® During HIMSS Annual Conference

ATLANTA and ORLANDO, Fla., Feb. 24, 2014 /PRNewswire/ -- Today at the HIMSS Annual Conference and Exhibition in Orlando, Sensiotec, a wireless digital technology leader, announces Version 2.0 of its Virtual Medical Assistant^® (VMA). VMA is the world's first non-contact remote vital signs monitor, offering a non-invasive device with no electrodes or leads to monitor patient presence, motion and vitals.

VMA 2.0 includes proprietary software and hardware enhancements to further expand the platform's integration capabilities with a special focus on enabling developers to use the information from VMA's patented Bed Sensor Panel in their own applications, products and services. Starting today, Sensiotec is accepting applications from innovative health tech companies whose efforts are in line with Sensiotec's mission: To install Virtual Medical Assistant^® in every unmonitored bed and improve healthcare for the better. 

"We continue to enhance our offering to increase the quality and lower the cost of patient monitoring," states Robert Arkin, CEO and founder of Sensiotec. "The integration capabilities of VMA 2.0 positions us to expand into new markets, create new distribution channels and engage innovative partners and customers."

Launch of Partnership Program
VGBio, a predictive analytics provider, is the first company to be accepted into Sensiotec's Premiere Partnership Program. It is implementing VMA's 2.0 platform into VGBio's VitaLink™ remote patient monitoring solution to record data and build personalized physiology models for patients with Chronic Obstructive Pulmonary Disease (COPD). VitaLink™ was developed in part under a contract with the US Department of Veterans Affairs, Center for Innovation and is currently the subject of two IRB approved clinical studies with the VA and University of Chicago Medical Center. The goal of the partnership is to use the data from the combined solution to predict and prevent emergency room visits for this group of patients.

"Never before in medical history have we had the opportunity to computationally analyze so many different data points about a person's health. The integration capabilities of VMA's 2.0 platform provide an unprecedented chance to find important correlations," explains Dr. Jiten Chhabra, research scientist with Georgia Tech's Interactive Media Technology Center. "Sensiotec's partnership with VGBio to use VMA for COPD monitoring is a great example of technology enabled collaboration that will change healthcare for the better." 

Sensiotec will demonstrate VMA 2.0 during HIMSS this week and attendees can see the device in action by visiting both the Intelligent Hospital Pavilion and the Intelligent Medical Home - Acute Bedroom. "What Sensiotec has unveiled for the industry is truly innovative. There has always been a great deal of pressure placed on developing new solutions to help healthcare providers become more efficient, and Sensiotec is leading the charge for our industry with VMA. We are pleased to have the company included in the HIMSS Intelligent Hospital Pavilion," says Dr. Paul Frisch, president and CTO, Intelligent Health Association.

If you are interested in joining Sensiotec's Premiere Partnership Program, please email [email protected]. To learn more about Sensiotec and VMA please visit, www.Sensiotec.com.

About Sensiotec
Sensiotec, a wireless digital technology leader, pioneered the world's first non-contact remote vital signs monitor, offering an invisible, non-wearable system to measure heart rate, respiration rate, bed occupancy, and movement—Virtual Medical Assistant® (VMA). VMA allows healthcare providers to access real-time and trend data which can be sent to any remote device. Implementing VMA into hospitals will reduce risk, cost, enhance productivity, improve the quality of patient care and increase patient satisfaction. Sensiotec received the Healthcare Heroes Award for Innovation for development of VMA. For more information, visit www.Sensiotec.com or www.twitter.com/Sensiotec. 

SOURCE Sensiotec